IP Library › Granted Patent US 12,703,860
Granted Patent B2
US 12,703,860 · App. 17/919,649 · Granted Aug 11, 2026

Terminal deoxynucleotidyl transferase variants and uses thereof

Inventors: Mikhael Soskine (Franconville, FR); Elise Champion (Paris, FR)
Assignee: DNA Script
C12N9/1264C12Y207/07031C12N2310/321
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,703,860
App. No.
17/919,649
Filed
Oct 18, 2022
Granted
Aug 11, 2026
Kind
B2
Art Unit
1652
USPC
435/194
Abstract

The present invention is directed to terminal deoxynucleotidyl transferase (TdT) variants from a variety of species which display enhanced efficiency in incorporating reversibly blocked nucleoside triphosphates into a polynucleotide, and to the use of such TdTs in synthesizing polynucleotides of any predetermined sequence.

Claims (91)

1 . A terminal deoxynucleotidyl transferase (TdT) variant comprising an amino acid sequence at least ninety percent identical to an amino acid sequence selected from SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23 26, 29, 32, 35, 38, 41, 44 or 47, wherein:

with respect to SEQ ID NO: 2 leucine at position 61 is substituted, cysteine at position 170 is substituted, arginine at position 204 is substituted, arginine at position 326 is substituted and glycine at position 329 is substituted;

with respect to SEQ ID NO: 5 leucine at position 48 is substituted, cysteine at position 158 is substituted, arginine at position 192 is substituted, arginine at position 314 is substituted and glycine at position 317 is substituted;

with respect to SEQ ID NO: 8 leucine at position 61 is substituted, tyrosine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 327 is substituted and glutamic acid at position 329 is substituted;

with respect to SEQ ID NO: 11 leucine at position 61 is substituted, tyrosine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 324 is substituted and glutamic acid at position 327 is substituted;

with respect to SEQ ID NO: 14 glycine at position 61 is substituted, arginine at position 205 is substituted, arginine at position 327 is substituted and glutamic acid at position 330 is substituted;

with respect to SEQ ID NO: 17 arginine at position 61 may or may not be substituted, alanine at position 158 is substituted, arginine at position 192 is substituted, arginine at position 311 is substituted and glutamic acid at position 314 is substituted;

with respect to SEQ ID NO: 20 arginine at position 61 may or may not be substituted, proline at position 171 may or may not be substituted, arginine at position 205 is substituted, threonine at position 321 is substituted and glutamic acid at position 324 is substituted;

with respect to SEQ ID NO: 23 arginine at position 61 may or may not be substituted, alanine at position 171 may or may not be substituted, arginine at position 205 is substituted, alanine at position 322 may or may not be substituted and glutamic acid at position 325 is substituted;

with respect to SEQ ID NO: 26 arginine at position 61 may or may not be substituted, alanine at position 171 may or may not be substituted, arginine at position 205 is substituted, arginine at position 322 is substituted and glutamic acid at position 325 is substituted;

with respect to SEQ ID NO: 29 methionine at position 48 is substituted, cysteine at position 158 is substituted, arginine at position 192 is substituted, arginine at position 310 is substituted and glutamic acid at position 313 is substituted;

with respect to SEQ ID NO: 32 methionine at position 61 is substituted, cysteine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 323 is substituted and glutamic acid at position 326 is substituted;

with respect to SEQ ID NO: 35 methionine at position 61 is substituted, cysteine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 323 is substituted and glutamic acid at position 326 is substituted;

with respect to SEQ ID NO: 38 methionine at position 61 is substituted, cysteine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 323 is substituted and glutamic acid at position 326 is substituted;

with respect to SEQ ID NO: 41 methionine at position 61 is substituted, cysteine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 323 is substituted and glutamic acid at position 326 is substituted;

with respect to SEQ ID NO: 44 methionine at position 48 is substituted, cysteine at position 158 is substituted, arginine at position 192 is substituted, arginine at position 309 is substituted and glutamic acid at position 312 is substituted; or

with respect to SEQ ID NO: 47 methionine at position 61 is substituted, cysteine at position 171 is substituted, arginine at position 205 is substituted, arginine at position 323 is substituted and glutamic acid at position 326 is substituted; and

wherein the TdT variant

(i) is capable of synthesizing a nucleic acid fragment without a template and

(ii) (ii) is capable of incorporating a 3′-O-modified nucleotide onto a free 3′-hydroxyl of a nucleic acid fragment.

2 . The TdT variant of claim 1 , wherein:

said substitution for leucine at position 61 in SEQ ID NO: 2, 8 or 11 or position 48 in SEQ ID NO: 5 is selected from the group consisting of R or Q;

said substitution for cysteine at position 170 in SEQ ID NO: 2 or position 158 in SEQ ID NO: 5, 29 or 44 or position 171 in SEQ ID NO: 32, 35, 38, 41 or 47 is selected from the group consisting of G, R, P, A, V, S, N, Q or D; and in other embodiments, the substitution for cysteine at the foregoing positions is selected from the group consisting of G or R;

said substitution for tyrosine at position 171 of SEQ ID NO: 8 or 11 is selected from the group consisting of G, R, P, A, V, S, N, Q or D; and in other embodiments, the substitution for tyrosine at the foregoing positions is selected from the group consisting of G or R;

said substitution for alanine at position 158 of SEQ ID NO: 17 or position 171 of SEQ ID NO: 23 or 26 is selected from the group consisting of G, R, P, V, S, N, Q or D; and in other embodiments, the substitution for alanine at the foregoing positions is selected from the group consisting of G or R;

said substitution for proline at position 171 of SEQ ID NO: 20 is selected from the group consisting of G, R, A, V, S, N, Q or D; and in other embodiments, the substitution for tyrosine at the foregoing positions is selected from the group consisting of G or R;

said substitution for arginine at position 204 of SEQ ID NO: 2 or position 192 of SEQ ID NO: 5, 17, 29 or 44 or position 205 of SEQ ID NO: 8, 11, 14, 20, 23, 26, 32, 35, 38, 41 or 47 is selected from the group consisting of L or N;

said substitution for arginine at position 326 of SEQ ID NO: 2 or position 314 of SEQ ID NO: 5 or position 327 of SEQ ID NO: 8 or 14 or position 324 of SEQ ID NO: 11 or position 311 of SEQ ID NO: 17 or position 321 of SEQ ID NO: 20 or position 322 of SEQ ID NO: 23 or 26 or position 310 of SEQ ID NO: 29 or position 323 of SEQ ID NO: 32, 35, 38, 41 or 47 or position 309 of SEQ ID NO: 44 is selected from the group consisting of P, N or A;

said substitution for threonine at position 321 of SEQ ID NO: 20 is selected from the group consisting of P, N or A;

said substitution for glycine at position 329 of SEQ ID NO: 2 or 5 is selected from the group consisting of N, L, T or S; or

said substitution for glutamic acid at position 330 of SEQ ID NO: 8 or 14 or position 327 of SEQ ID NO: 11 or position 311 of SEQ ID NO: 17 or position 324 of SEQ ID NO: 20 or position 325 of SEQ ID NO: 23 or 26 or position 313 of SEQ ID NO: 29 position 326 of SEQ ID NO: 32, 35, 38, 41 or 47 or position 312 of SEQ ID NO: 44 is selected from the group consisting of N, L, T or S.

3 . The TdT variant of claim 1 , wherein:

with respect to SEQ ID NO: 2 glutamine at position 327 is substituted;

with respect to SEQ ID NO: 5 glutamic acid at position 315 is substituted;

with respect to SEQ ID NO: 8 glutamine at position 328 is substituted;

with respect to SEQ ID NO: 11 glutamine at position 325 is substituted;

with respect to SEQ ID NO: 14 glutamine at position 328 is substituted;

with respect to SEQ ID NO: 17 glutamine at position 312 is substituted;

with respect to SEQ ID NO: 20 glutamine at position 322 is substituted;

with respect to SEQ ID NO: 23 glutamine at position 323 is substituted;

with respect to SEQ ID NO: 26 methionine at position 323 is substituted;

with respect to SEQ ID NO: 29 glutamine at position 311 is substituted;

with respect to SEQ ID NO: 32 glutamine at position 324 is substituted;

with respect to SEQ ID NO: 35 glutamine at position 324 is substituted;

with respect to SEQ ID NO: 38 glutamine at position 324 is substituted;

with respect to SEQ ID NO: 41 glutamine at position 324 is substituted;

with respect to SEQ ID NO: 44 glutamine at position 310 is substituted; or

with respect to SEQ ID NO: 47 glutamine at position 324 is substituted.

4 . The TdT variant of claim 3 , wherein said glutamine is substituted with an amino acid selected from the group consisting of T, F, L, M, I, V and Y.

5 . The TdT variant of claim 1 , wherein said 3′-O-modified nucleotide is selected from the group consisting of 3′-O-amino-2′-deoxynucleoside triphosphate, 3′-O-azidomethyl-2′-deoxynucleoside triphosphate and 3′-O-allyl-2′-deoxynucleoside triphosphate.

6 . A terminal deoxynucleotidyl transferase (TdT) variant comprising an amino acid sequence at least ninety percent identical to an amino acid sequence selected from SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 or 48, wherein:

with respect to SEQ ID NO: 3 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 327 is A, and amino acid position 330 is N;

with respect to SEQ ID NO: 6 amino acid position 48 is R, amino acid position 158 is R, amino acid position 192 is L, amino acid position 314 is P, and amino acid position 317 is N;

with respect to SEQ ID NO: 9 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 327 is A, and amino acid position 330 is N;

with respect to SEQ ID NO: 12 amino acid position 61 is R, amino acid position 171 is A, amino acid position 205 is L, amino acid position 324 is P, and amino acid position 327 is N;

with respect to SEQ ID NO: 15 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 328 is P, and amino acid position 331 is N;

with respect to SEQ ID NO: 18 amino acid position 48 is R, amino acid position 158 is R, amino acid position 192 is L, amino acid position 311 is P, and amino acid position 314 is N;

with respect to SEQ ID NO: 21 amino acid position 61 is R, amino acid position 171 is P, amino acid position 205 is L, amino acid position 321 is A, and amino acid position 324 is N;

with respect to SEQ ID NO: 24 amino acid position 61 is R, amino acid position 171 is A, amino acid position 205 is L, amino acid position 322 is A, and amino acid position 325 is N;

with respect to SEQ ID NO: 27 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 327 is A, and amino acid position 330 is N;

with respect to SEQ ID NO: 30 amino acid position 48 is R, amino acid position 158 is R, amino acid position 192 is L, amino acid position 310 is P, and amino acid position 313 is N;

with respect to SEQ ID NO: 33 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 323 is P, and amino acid position 326 is N;

with respect to SEQ ID NO: 36 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 323 is A, and amino acid position 326 is N;

with respect to SEQ ID NO: 39 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 323 is P, and amino acid position 326 is N;

with respect to SEQ ID NO: 42 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 323 is A, and amino acid position 326 is N;

with respect to SEQ ID NO: 45 amino acid position 48 is R, amino acid position 158 is R, amino acid position 192 is L, amino acid position 310 is A, and amino acid position 313 is N; or

with respect to SEQ ID NO: 48 amino acid position 61 is R, amino acid position 171 is R, amino acid position 205 is L, amino acid position 323 is P, and amino acid position 326 is N; and

wherein the TdT variant

(i) is capable of synthesizing a nucleic acid fragment without a template and

(ii) (ii) is capable of incorporating a 3′-O-modified nucleotide onto a free 3′-hydroxyl of a nucleic acid fragment.

7 . The TdT variant of claim 6 , wherein:

with respect to SEQ ID NO: 3 amino acid position 328 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 6 amino acid position 315 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 9 amino acid position 328 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 12 amino acid position 325 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 15 amino acid position 329 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 18 amino acid position 312 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 21 amino acid position 322 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 24 amino acid position 323 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 27 amino acid position 328 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 30 amino acid position 311 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 33 amino acid position 324 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 36 amino acid position 324 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 39 amino acid position 324 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 42 amino acid position 324 is Q or is selected from the group consisting of T, F, L or M;

with respect to SEQ ID NO: 45 amino acid position 311 is Q or is selected from the group consisting of T, F, L or M; or

with respect to SEQ ID NO: 48 amino acid position 324 is Q or is selected from the group consisting of T, F, L or M.

8 . The TdT variant of claim 6 wherein said 3′-O-modified nucleotide is selected from the group consisting of 3′-O-amino-2′-deoxynucleoside triphosphate, 3′-O-azidomethyl-2′-deoxynucleoside triphosphate and 3′-O-allyl-2′-deoxynucleoside triphosphate.

9 . A terminal deoxynucleotidyl transferase (TdT) variant comprising an amino acid sequence at least ninety percent identical to an amino acid sequence selected from SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 or 48, and wherein the TdT variant

(i) is capable of synthesizing a nucleic acid fragment without a template and

(ii) is capable of incorporating a 3′-O-modified nucleotide onto a free 3′-hydroxyl of a polynucleotide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2022
From: SOSKINE, MIKHAEL; CHAMPION, ELISE
To: DNA SCRIPT
Reel/Frame 061486/0310 →
Priority Claims (1)
EP 20170405 · Apr 20, 2020 · regional
Continuity (1)
Related Publication 20230159903A1 · May 25, 2023
References Cited (131)
US 5367066A · Urdea et al. · 1994 [cited by applicant]
US 5436143A · Hyman · 1995 [cited by applicant]
US 5700642A · Monforte et al. · 1997 [cited by applicant]
US 5739386A · Holmes · 1998 [cited by applicant]
US 5744595A · Srivastava et al. · 1998 [cited by applicant]
US 5763594A · Hiatt et al. · 1998 [cited by applicant]
US 5808045A · Hiatt et al. · 1998 [cited by applicant]
US 5830655A · Monforte et al. · 1998 [cited by applicant]
US 6664097B2 · Russell et al. · 2003 [cited by applicant]
US 7057026B2 · Barnes et al. · 2006 [cited by applicant]
US 7544794B1 · Benner · 2009 [cited by applicant]
US 8034923B1 · Benner et al. · 2011 [cited by applicant]
US 8212020B2 · Benner et al. · 2012 [cited by applicant]
US 8808988B2 · Zhao et al. · 2014 [cited by applicant]
US 9410197B2 · Bergmann et al. · 2016 [cited by applicant]
US 10435676B2 · Champion · 2019 [cited by examiner]
US 10472383B2 · Benner · 2019 [cited by applicant]
US 10752887B2 · Champion · 2020 [cited by examiner]
US 10837040B2 · Ybert et al. · 2020 [cited by applicant]
US 10913964B2 · Ybert et al. · 2021 [cited by applicant]
US 11059849B2 · Ybert et al. · 2021 [cited by applicant]
US 11208637B2 · Champion · 2021 [cited by examiner]
US 11268091B2 · Godron · 2022 [cited by examiner]
US 11359221B2 · Creton · 2022 [cited by examiner]
US 11390856B2 · Ybert et al. · 2022 [cited by applicant]
US 11685941B2 · Ybert et al. · 2023 [cited by applicant]
US 11859217B2 · Champion · 2024 [cited by examiner]
US 11905541B2 · Creton · 2024 [cited by examiner]
US 11993773B2 · Godron · 2024 [cited by examiner]
US 12065461B2 · Sarac et al. · 2024 [cited by applicant]
US 12071638B2 · Champion · 2024 [cited by examiner]
US 12286652B2 · Champion · 2025 [cited by examiner]
US 20030186226A1 · Brennan et al. · 2003 [cited by applicant]
US 20040106728A1 · McGall et al. · 2004 [cited by applicant]
US 20050037991A1 · Bodepudi et al. · 2005 [cited by applicant]
US 20190078065A1 · Baiga et al. · 2019 [cited by applicant]
US 20190078126A1 · Baiga et al. · 2019 [cited by applicant]
US 20190211315A1 · Champion et al. · 2019 [cited by applicant]
US 20190264248A1 · Ybert · 2019 [cited by examiner]
US 20190300923A1 · Ybert et al. · 2019 [cited by applicant]
US 20190390178A1 · Champion et al. · 2019 [cited by applicant]
US 20200002690A1 · Ybert et al. · 2020 [cited by applicant]
US 20200231619A1 · Ybert et al. · 2020 [cited by applicant]
US 20200370027A1 · Ybert et al. · 2020 [cited by applicant]
US 20210009970A1 · Champion et al. · 2021 [cited by applicant]
US 20210130863A1 · Ybert et al. · 2021 [cited by applicant]
US 20210214382A1 · Sarac et al. · 2021 [cited by applicant]
US 20210332351A1 · Horgan et al. · 2021 [cited by applicant]
US 20220002687A1 · Champion et al. · 2022 [cited by applicant]
US 20220315970A1 · Horgan · 2022 [cited by applicant]
US 20220356510A1 · Godron et al. · 2022 [cited by applicant]
US 20220403354A1 · Champion et al. · 2022 [cited by applicant]
US 20220403434A1 · Heinisch et al. · 2022 [cited by applicant]
US 20220403435A1 · Horgan et al. · 2022 [cited by applicant]
US 20220403436A1 · Horgan et al. · 2022 [cited by applicant]
US 20220411840A1 · Champion et al. · 2022 [cited by applicant]
US 20230062303A1 · Champion et al. · 2023 [cited by applicant]
US 20230089448A1 · Horgan et al. · 2023 [cited by applicant]
US 20230167421A1 · Ybert et al. · 2023 [cited by applicant]
US 20230193222A1 · Ybert et al. · 2023 [cited by applicant]
US 20230203553A1 · Ybert · 2023 [cited by applicant]
US 20230241571A1 · Martin et al. · 2023 [cited by applicant]
US 20230313255A1 · Horgan et al. · 2023 [cited by applicant]
US 20230416708A1 · Loftie-Eaton et al. · 2023 [cited by applicant]
US 20240052391A1 · Godron et al. · 2024 [cited by applicant]
US 20240093165A1 · Champion et al. · 2024 [cited by applicant]
US 20240093256A1 · Soskine et al. · 2024 [cited by applicant]
US 20240124855A1 · Ybert et al. · 2024 [cited by applicant]
US 20240254459A1 · Champion et al. · 2024 [cited by applicant]
US 20240279700A1 · Horgan · 2024 [cited by applicant]
CN 107567501A · 2018 [cited by applicant]
CN 110997907A · 2020 [cited by applicant]
WO WO1991006678 · 1991 [cited by applicant]
WO WO2004005667 · 2004 [cited by applicant]
WO WO2015159023 · 2015 [cited by applicant]
WO 2016034807A1 · 2016 [cited by applicant]
WO WO2017216472 · 2017 [cited by applicant]
WO 2018215803A1 · 2018 [cited by applicant]
WO 2019030149A1 · 2019 [cited by applicant]
WO WO2019135007 · 2019 [cited by applicant]
WO 2020020608A1 · 2020 [cited by applicant]
WO 2020043846A1 · 2020 [cited by applicant]
WO 2020099451A1 · 2020 [cited by applicant]
WO 2020120442A2 · 2020 [cited by applicant]
WO 2020141143A1 · 2020 [cited by applicant]
WO 2021018919A1 · 2021 [cited by applicant]
WO 2021018921A1 · 2021 [cited by applicant]
WO 2021048142A1 · 2021 [cited by applicant]
WO 2021058438A1 · 2021 [cited by applicant]
WO 2021094251A1 · 2021 [cited by applicant]
WO 2021116270A1 · 2021 [cited by applicant]
WO 2021122539A1 · 2021 [cited by applicant]
WO 2021170524A1 · 2021 [cited by applicant]
WO 2021254934A1 · 2021 [cited by applicant]
WO 2022013094A1 · 2022 [cited by applicant]
WO 2022063835A1 · 2022 [cited by applicant]
WO 2022090057A1 · 2022 [cited by applicant]
WO 2022090323A1 · 2022 [cited by applicant]
WO 2022207934A1 · 2022 [cited by applicant]
WO 2022258809A1 · 2022 [cited by applicant]
WO 2023025488A1 · 2023 [cited by applicant]
WO 2023083997A2 · 2023 [cited by applicant]
WO 2023083999A2 · 2023 [cited by applicant]
WO 2023170266A1 · 2023 [cited by applicant]
Bornscheuer et al. Curr Protoc Protein Sci. Nov. 2011;Chapter 26:Unit26.7 (Year: 2011). [cited by examiner]
Accession BDD30476. Sep. 22, 2016. (Year: 2016). [cited by examiner]
Becker et al. (1967) “The Enzymatic Cleavage of Phosphate Termini from Polynucleotides”, The Journal of Biological Chemistry, 242(5): 936-950. [cited by applicant]
Bentolila et al (1995) “The Two Isoforms of Mouse Terminal Deoxynucleotidyl Transferase Differ in Both the Ability to Add N Regions and Subcellular Localization”, The EMBO Journal, 14(17): 4221-4229. [cited by applicant]
Boule et al (1998) “High-Level Expression of Murine Terminal Deoxynucleotidyl Transferase in [cited by applicant]
Cameron et al. (1977) “3′-Phosphatase Activity in T4 Polynucleotide Kinase”, Biochemistry, 16(23): 5120-5126. [cited by applicant]
Canard et al. (1994) “DNA Polymerase Fluorescent Substrates with Reversible 3′-Tags”, Gene., 148(1): 1-6. [cited by applicant]
Canard et al. (1995) “Catalytic Editing Properties of DNA Polymerases”, Proc Natl. Acad. Sci, 92(24): 10859-10863. [cited by applicant]
Corpet (1988) “Multiple sequence alignment with hierarchical clustering”, Nucleic Acids Research, 16(22): 10881-10890. [cited by applicant]
Ferrero et al. (2000) “Chemoenzymatic Transformations in Nucleoside Chemistry”, Monatshefte fur Chemie 131: 585-616. [cited by applicant]
Grantham, R. (1974) “Amino Acid Difference Formula to Help Explain Protein Evolution”, Science, 185: 862-864. [cited by applicant]
Guo et al. (2008) “Four-color DNA Sequencing with 3′-O-Modified Nucleotide Reversible Terminators and Chemically Cleavable Fluorescent Dideoxynucleotides”, Proc. Natl. Acad. Sci., 105(27): 9145-9150. [cited by applicant]
Jensen et al (2018) “Template-Independent Enzymatic Oligonucleotide Synthesis (TiEOS)”, Biochemistry, 57(12): 1821-1832. [cited by applicant]
Kodumal et al (2004) “Total synthesis of long DNA sequences: Synthesis of acontiguous 32-kb polyketide synthase gene cluster”, The National Academy of Sciences of the USA, 101(44): 15573-15578. [cited by applicant]
Mathews et al. (2016) “Photo-Cleavable Nucleotides for Primer Free Enzyme Mediated DNA Synthesis”, Organic & Biomolecular Chemistry, 14(35): 8278-8288. [cited by applicant]
Meng et al. (2006) “Design and Synthesis of a Photocleavable Fluorescent Nucleotide 3′-O-Allyl-dGTP-PC-Bodipy-FL-510 as a Reversible Terminator for DNA Sequencing by Synthesis”, J. Org. Chem., 71(8): 3248-3252. [cited by applicant]
Metzker et al. (1994) “Termination of DNA Synthesis by Novel 3′-Modifieddeoxyribonucleoside 5′-Triphosphates”, Nucleic Acids Research, 22(20): 4259-4267. [cited by applicant]
Rasolonjatovo et al. (1999) “Development of a New DNA Sequencing Method: 3′-Ester Cleavage Catalyzed by Taq DNA Polymerase”, Nucleosides & Nucleotides, 18(4&5): 1021-1022. [cited by applicant]
Schmitz et al. (1999) “Solid-Phase Enzymatic Synthesis of Oligonucleotides”, Organic Letters, 1(11): 1729-1731. [cited by applicant]
Stemmer et al (1995) “Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides”, Gene, 164: 49-53. [cited by applicant]
Taunton-Rigby, Alison (1973) “Oligonucleotide Synthesis. III. Enzymatically Removable Acyl Protecting Groups”, J. Org. Chem., 38(5): 977-985. [cited by applicant]
Uemura et al. (1989) “Regioselective Deprotection of 3′,5′-O-Acylated Pyrimidine Nucleosides by Lipase and Esterase”, Tetrahedron Letters, 30(29): 3819-3820. [cited by applicant]
Altschul, S. F. et al. (2005). “Protein Database Searches Using Compositionally Adjusted,” FEBS J. 272:5101-5109. [cited by applicant]
Altschul, S.F. et al. (1997). “Gapped BLAST and PSI-BLAST: A new Generation of Protein Database Search Programs,” Nucleic Acids Research 25(17):3389-3402. [cited by applicant]
Repasky, J.A.E. et al. (2004). “Mutational Analysis of Terminal Deoxynucleotidyltransferase-Mediated N-Nucleotide Addition in V(D)J Recombination,” The Journal of Immunology 172(9):5478-5488, 12 pages. [cited by applicant]
Smith, T.F. et al. (1981). “Identification of Common Molecular Subsequence,” J. Mol. Biol. 147:195-197. [cited by applicant]
GenBank Accession No. XP_003133204.1, last updated May 13, 2017, located at <http://www.ncbi.nlm.nih.gov/protein/XP_003133204.1>, last visited on Sep. 4, 2025, two pages. [cited by applicant]